Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
fibrosis10255 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A49353 | 35780715 | Growth Horm IGF Res | Expression of IGF-1 receptor and GH receptor in hepatic tissue of patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. | 2022 | Details |
| A49356 | 35779422 | Biomed Pharmacother | Recent advances in lean NAFLD. | 2022 | Details |
| A49358 | 35779256 | J Clin Endocrinol Metab | The GH/IGF-1 axis is associated with intrahepatic lipid content and hepatocellular damage in overweight/obesity. | 2022 | Details |
| A49366 | 35777449 | Biochem Pharmacol | Ceramide de novo synthesis in non-alcoholic fatty liver disease: Pathogenic mechanisms and therapeutic perspectives. | 2022 | Details |
| A49368 | 35774609 | Front Pharmacol | Exploring Ganweikang Tablet as a Candidate Drug for NAFLD Through Network Pharmacology Analysis and Experimental Validation. | 2022 | Details |
| A49369 | 35773644 | BMC Gastroenterol | Evaluating future risk of NAFLD in adolescents: a prediction and decision curve analysis. | 2022 | Details |
| A49377 | 35769208 | Mediators Inflamm | MFG-E8 Knockout Aggravated Nonalcoholic Steatohepatitis by Promoting the Activation of TLR4/NF-κB Signaling in Mice. | 2022 | Details |
| A49390 | 35766414 | J Clin Endocrinol Metab | Fibrosis Risk in Nonalcoholic Fatty Liver Disease is Related to Chronic Kidney Disease in Aged Type 2 Diabetes Patients. | 2022 | Details |
| A49392 | 35765700 | Hepatol Commun | Growth hormone deficiency and NAFLD: An overlooked and underrecognized link. | 2022 | Details |
| A49396 | 35765026 | J Transl Med | Rhubarb free anthraquinones improved mice nonalcoholic fatty liver disease by inhibiting NLRP3 inflammasome. | 2022 | Details |
| A49407 | 35760372 | Diabetes Metab | Prevalence and predictors of non-alcoholic steatohepatitis in subjects with morbid obesity and with or without type 2 diabetes. | 2022 | Details |
| A49409 | 35760093 | Life Sci | The role of protein kinases as key drivers of metabolic dysfunction-associated fatty liver disease progression: New insights and future directions. | 2022 | Details |
| A49412 | 35758506 | J Pediatr Gastroenterol Nutr | Autoimmune Antibodies in Children and Adolescents with Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A49417 | 35757404 | Front Endocrinol (Lausanne) | Hepatic Stellate Cell-Immune Interactions in NASH. | 2022 | Details |
| A49421 | 35757147 | Int J Cardiol Heart Vasc | Synergistic effects of liver fibrosis and sarcopenia on endothelial dysfunction and arterial stiffness in patients with type 2 diabetes. | 2022 | Details |
| A49422 | 35757117 | Front Pediatr | Prevalence and Risk Factors for Hepatic Steatosis in Children With Perinatal HIV on Early Antiretroviral Therapy Compared to HIV-Exposed Uninfected and HIV-Unexposed Children. | 2022 | Details |
| A49432 | 35750138 | J Hepatol | Soluble TREM2 levels reflect the recruitment and expansion of TREM2+ macrophages that localize to fibrotic areas and limit NASH. | 2022 | Details |
| A49433 | 35750137 | J Hepatol | Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits. | 2022 | Details |
| A49434 | 35749236 | J Nat Prod | Xyloketal B Reverses Nutritional Hepatic Steatosis, Steatohepatitis, and Liver Fibrosis through Activation of the PPARα/PGC1α Signaling Pathway. | 2022 | Details |
| A49442 | 35748302 | J Gastroenterol Hepatol | Circulating adiponectin in patients with nonalcoholic fatty liver disease-related liver fibrosis: a systematic review and a meta-analysis. | 2022 | Details |
| A49449 | 35745284 | Nutrients | Relation of Dietary Patterns and Nutritional Profile to Hepatic Fibrosis in a Sample of Lebanese Non-Alcoholic Fatty Liver Disease Patients. | 2022 | Details |
| A49453 | 35745223 | Nutrients | Very Low Alcohol Consumption Is Associated with Lower Prevalence of Cirrhosis and Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease. | 2022 | Details |
| A49455 | 35745142 | Nutrients | Alisol B Alleviates Hepatocyte Lipid Accumulation and Lipotoxicity via Regulating RARα-PPARγ-CD36 Cascade and Attenuates Non-Alcoholic Steatohepatitis in Mice. | 2022 | Details |
| A49461 | 35744805 | Molecules | Drugs Targeting the A3 Adenosine Receptor: Human Clinical Study Data. | 2022 | Details |
| A49463 | 35744053 | Medicina (Kaunas) | Deuterium-Reinforced Polyunsaturated Fatty Acids Prevent Diet-Induced Nonalcoholic Steatohepatitis by Reducing Oxidative Stress. | 2022 | Details |
| A49464 | 35744024 | Medicina (Kaunas) | An Update on the Chemokine System in the Development of NAFLD. | 2022 | Details |
| A49469 | 35743358 | J Clin Med | When Sugar Reaches the Liver: Phenotypes of Patients with Diabetes and NAFLD. | 2022 | Details |
| A49473 | 35743140 | Int J Mol Sci | Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis. | 2022 | Details |
| A49477 | 35740949 | Biomolecules | NAFLD: Mechanisms, Treatments, and Biomarkers. | 2022 | Details |
| A49479 | 35740337 | Biomedicines | Identification of the Potential Molecular Mechanisms Linking RUNX1 Activity with Nonalcoholic Fatty Liver Disease, by Means of Systems Biology. | 2022 | Details |
| A49480 | 35740312 | Biomedicines | Hepatic Mitochondrial Dysfunction and Risk of Liver Disease in an Ovine Model of "PCOS Males". | 2022 | Details |
| A49482 | 35740267 | Biomedicines | Combined Effects of Chronic Kidney Disease and Nonalcoholic Fatty Liver Disease on the Risk of Cardiovascular Disease in Patients with Diabetes. | 2022 | Details |
| A49492 | 35738255 | Semin Liver Dis | Intestinal Barrier Dysfunction in Fatty Liver Disease: Roles of Microbiota, Mucosal Immune System, and Bile Acids. | 2022 | Details |
| A49496 | 35736460 | Metabolites | A Quantitative Systems Pharmacology Platform Reveals NAFLD Pathophysiological States and Targeting Strategies. | 2022 | Details |
| A49497 | 35736447 | Metabolites | Interactions between Tryptophan Metabolism, the Gut Microbiome and the Immune System as Potential Drivers of Non-Alcoholic Fatty Liver Disease (NAFLD) and Metabolic Diseases. | 2022 | Details |
| A49501 | 35735003 | J Int Med Res | Combinational elastography for assessment of liver fibrosis in patients with liver injury. | 2022 | Details |
| A49504 | 35733806 | Front Pediatr | Higher Levels of Plasma Hyaluronic Acid and N-terminal Propeptide of Type III Procollagen Are Associated With Lower Kidney Function in Children With Non-alcoholic Fatty Liver Disease. | 2022 | Details |
| A49509 | 35731428 | Dig Dis Sci | Crohn's Disease Is Associated with Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A49512 | 35730208 | Clin Mol Hepatol | Auranofin attenuates hepatic steatosis and fibrosis in non-alcoholic fatty liver disease via NRF2 and NF-κB signaling pathways. | 2022 | Details |
| A49515 | 35728962 | Cas Lek Cesk | An overview of current therapy options of non-alcoholic fatty liver disease. | 2022 | Details |
| A49523 | 35727151 | Radiology | Two-dimensional Shear-Wave Elastography and US Attenuation Imaging for Nonalcoholic Steatohepatitis Diagnosis: A Cross-sectional, Multicenter Study. | 2022 | Details |
| A49526 | 35726536 | Eur J Histochem | Ferroptosis resistance cooperates with cellular senescence in the overt stage of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. | 2022 | Details |
| A49527 | 35726152 | Endocrinol Metab (Seoul) | The Impact of Insulin Resistance on Hepatic Fibrosis among United States Adults with Non-Alcoholic Fatty Liver Disease: NHANES 2017 to 2018. | 2022 | Details |
| A49528 | 35725929 | Genes Immun | The presence of interferon affects the progression of non-alcoholic fatty liver disease. | 2022 | Details |
| A49536 | 35721884 | World J Gastroenterol | Gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced magnetic resonance imaging for evaluating fibrosis regression in chronic hepatitis C patients after direct-acting antiviral. | 2022 | Details |
| A49539 | 35721296 | World J Hepatol | Prognostic non-invasive biomarkers for all-cause mortality in non-alcoholic fatty liver disease: A systematic review and meta-analysis. | 2022 | Details |
| A49543 | 35720958 | 3 Biotech | Amelioration of high-fat diet (HFD) + CCl4 induced NASH/NAFLD in CF-1 mice by activation of SIRT-1 using cinnamoyl sulfonamide hydroxamate derivatives: in-silico molecular modelling and in-vivo prediction. | 2022 | Details |
| A49545 | 35720167 | World J Gastrointest Pathophysiol | Utility of FibroScan-based scoring systems to narrow the risk group of nonalcoholic fatty liver disease with comorbidities. | 2022 | Details |
| A49546 | 35720113 | Front Mol Biosci | Ferroptosis in Chronic Liver Diseases: Opportunities and Challenges. | 2022 | Details |
| A49551 | 35717907 | Biochem Biophys Res Commun | S100A9 promotes inflammatory response in diabetic nonalcoholic fatty liver disease. | 2022 | Details |
| A49553 | 35716542 | Phytomedicine | Phillygenin ameliorates nonalcoholic fatty liver disease via TFEB-mediated lysosome biogenesis and lipophagy. | 2022 | Details |
| A49556 | 35714879 | J Ethnopharmacol | Betulinic acid prevents liver fibrosis by binding Lck and suppressing Lck in HSC activation and proliferation. | 2022 | Details |
| A49558 | 35714570 | Biochem Biophys Res Commun | TSC22D4 promotes TGFβ1-induced activation of hepatic stellate cells. | 2022 | Details |
| A49560 | 35713854 | Obes Surg | Endoscopic Bariatric Treatment with Duodenal-Jejunal Bypass Liner Improves Non-invasive Markers of Non-alcoholic Steatohepatitis. | 2022 | Details |
| A49561 | 35713614 | Lab Med | Association of rs5742612 Polymorphism in the Promoter Region of IGF1 Gene with Nonalcoholic Fatty Liver Disease: A Case-Control Study. | 2022 | Details |
| A49564 | 35712786 | Hepatology | Circulating TREM2 as a non-invasive diagnostic biomarker for NASH in patients with elevated liver stiffness. | 2022 | Details |
| A49571 | 35709934 | Clin Gastroenterol Hepatol | Incidence of Type 2 Diabetes in Children With Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A49572 | 35709779 | Acta Gastroenterol Belg | Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far ? | 2022 | Details |
| A49575 | 35709466 | PLoS One | Prognostic impact of steatosis in the clinical course of chronic HCV infection-Results from the German Hepatitis C-Registry. | 2022 | Details |
| A49578 | 35708088 | Curr Stem Cell Res Ther | Co-culture of liver parenchymal cells with non-parenchymal cells under 2D and 3D culture systems; a review paper. | 2022 | Details |
| A49579 | 35708049 | Crit Rev Food Sci Nutr | Health benefits of astaxanthin against age-related diseases of multiple organs: A comprehensive review. | 2022 | Details |
| A49586 | 35702844 | J Assoc Physicians India | A Study on FibroScan and Endoscopic Finding in Patients of Chronic Liver Disease attending Tripura Medical College and Dr. B.R. Ambedkar Memorial Teaching Hospital. | 2022 | Details |
| A49587 | 35702836 | J Assoc Physicians India | Interrelation of the Risk Factors of NAFLD at various Stages of Progression of the glycemic Status on long-term Follow-up. | 2022 | Details |
| A49589 | 35701716 | Hepatol Int | A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population. | 2022 | Details |
| A49591 | 35700738 | Cell Metab | MiR-690 treatment causes decreased fibrosis and steatosis and restores specific Kupffer cell functions in NASH. | 2022 | Details |
| A49592 | 35700593 | Nutrition | Short-term high-fat and high-carbohydrate diets increase susceptibility to liver injury by inducing hepatic procoagulant and proinflammatory conditions with different balances. | 2022 | Details |
| A49593 | 35698652 | Diabetes Metab Syndr Obes | Fibrosis Predictive Score in Caucasian Patients with Metabolic Syndrome. | 2022 | Details |
| A49594 | 35697996 | Obes Surg | The Benefit of Bariatric Surgery on Histological Features of Metabolic Associated Fatty Liver Disease Assessed Through Noninvasive Methods. | 2022 | Details |
| A49599 | 35695040 | Expert Rev Mol Med | The potential role of FNDC5/irisin in various liver diseases: awakening the sleeping beauties. | 2022 | Details |
| A49608 | 35693370 | Cureus | Comparing the Efficacy and Safety of Obeticholic Acid and Semaglutide in Patients With Non-Alcoholic Fatty Liver Disease: A Systematic Review. | 2022 | Details |
| A49609 | 35692676 | J Clin Biochem Nutr | Pre-germinated brown rice alleviates non-alcoholic fatty liver disease induced by high fructose and high fat intake in rat. | 2022 | Details |
| A49612 | 35692179 | Obes Rev | Evaluation of nonalcoholic fatty liver disease (NAFLD) in severe obesity using noninvasive tests and imaging techniques. | 2022 | Details |
| A49613 | 35691383 | Environ Res | Association of blood manganese, selenium with steatosis, fibrosis in the National Health and Nutrition Examination Survey, 2017-18. | 2022 | Details |
| A49617 | 35690264 | J Hepatol | Porto-sinusoidal vascular disorder. | 2022 | Details |
| A49620 | 35689309 | Aliment Pharmacol Ther | Letter: non-invasive prediction models to exclude cirrhosis in NAFLD-not everyone fits the mould. Authors' reply. | 2022 | Details |
| A49621 | 35689091 | Acta Pharmacol Sin | Dectin-1 plays a deleterious role in high fat diet-induced NAFLD of mice through enhancing macrophage activation. | 2022 | Details |
| A49622 | 35688683 | Arab J Gastroenterol | Evaluation of hepatosteatosis in patients with chronic hepatitis B virus infection. | 2022 | Details |
| A49623 | 35688322 | J Pharmacol Toxicol Methods | Establishment of a new nonalcoholic steatohepatitis model; Ovariectomy exacerbates nonalcoholic steatohepatitis-like pathology in diabetic rats. | 2022 | Details |
| A49624 | 35688226 | J Hepatol | LIVER STIFFNESS, BUT NOT FATTY LIVER DISEASE, IS ASSOCIATED WITH ATRIAL FIBRILLATION: THE ROTTERDAM STUDY. | 2022 | Details |
| A49632 | 35684158 | Nutrients | 11β-HSD1 Inhibitor Alleviates Non-Alcoholic Fatty Liver Disease by Activating the AMPK/SIRT1 Signaling Pathway. | 2022 | Details |
| A49634 | 35684079 | Nutrients | Consumption of Low Dose Fucoxanthin Does Not Prevent Hepatic and Adipose Inflammation and Fibrosis in Mouse Models of Diet-Induced Obesity. | 2022 | Details |
| A49636 | 35683998 | Nutrients | Differential Effects of Dietary versus Exercise Intervention on Intrahepatic MAIT Cells and Histological Features of NAFLD. | 2022 | Details |
| A49639 | 35683431 | J Clin Med | Triglyceride and Glucose Index as a Screening Tool for Nonalcoholic Liver Disease in Patients with Metabolic Syndrome. | 2022 | Details |
| A49640 | 35682957 | Int J Mol Sci | Smad3 Phospho-Isoform Signaling in Nonalcoholic Steatohepatitis. | 2022 | Details |
| A49649 | 35679904 | J Lipid Res | Inhibition of MAP4K4 Signaling Initiaties Metabolic Reprogramming to Protect Hepatocytes from Lipotoxic Damage. | 2022 | Details |
| A49651 | 35678878 | Cell Mol Life Sci | The protective effect of selenoprotein M on non-alcoholic fatty liver disease: the role of the AMPKα1-MFN2 pathway and Parkin mitophagy. | 2022 | Details |
| A49656 | 35677516 | J Clin Exp Hepatol | The Association Between Chronic Plaque Psoriasis and Nonalcoholic Fatty Liver Disease in Indian Patients: Results of a Pilot Study. | 2021 | Details |
| A49660 | 35677506 | J Clin Exp Hepatol | Value of Liver Function Tests in Cirrhosis. | 2021 | Details |
| A49664 | 35677306 | Front Bioeng Biotechnol | AgNPs Aggravated Hepatic Steatosis, Inflammation, Oxidative Stress, and Epigenetic Changes in Mice With NAFLD Induced by HFD. | 2022 | Details |
| A49669 | 35675800 | Cell Metab | Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia. | 2022 | Details |
| A49675 | 35673598 | J Hepatocell Carcinoma | Hepatocellular Carcinoma Due to Nonalcoholic Fatty Liver Disease: Current Concepts and Future Challenges. | 2022 | Details |
| A49684 | 35671973 | Mol Metab | Sphingosine kinase 1 mediates sexual dimorphism in fibrosis in a mouse model of NASH. | 2022 | Details |
| A49685 | 35671811 | Life Sci | Vildagliptin alleviates liver fibrosis in NASH diabetic rats via modulation of insulin resistance, oxidative stress, and inflammatory cascades. | 2022 | Details |
| A49687 | 35670949 | Obes Surg | Serum Ferritin and NAFLD in Patients Undergoing Bariatric Surgery. | 2022 | Details |
| A49688 | 35670897 | Dig Dis Sci | Compensated Advanced Chronic Liver Disease in Nonalcoholic Fatty Liver Disease: Two-Step Strategy is Better than Baveno Criteria. | 2022 | Details |
| A49691 | 35668917 | J Inflamm Res | Melatonin Suppresses NLRP3 Inflammasome Activation via TLR4/NF-κB and P2X7R Signaling in High-Fat Diet-Induced Murine NASH Model. | 2022 | Details |
| A49697 | 35666557 | JMIR Med Inform | Noninvasive Diagnosis of Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis Using Machine Learning Methods: Comparative Study With Existing Quantitative Risk Scores. | 2022 | Details |
| A49699 | 35665350 | Front Med (Lausanne) | Association Between Monocyte to High-Density Lipoprotein Cholesterol Ratio and Risk of Non-alcoholic Fatty Liver Disease: A Cross-Sectional Study. | 2022 | Details |
| A49701 | 35665109 | World J Clin Cases | Metabolic dysfunction is associated with steatosis but no other histologic features in nonalcoholic fatty liver disease. | 2022 | Details |
| A49703 | 35664038 | World J Gastroenterol | Mechanisms of ductular reaction in non-alcoholic steatohepatitis. | 2022 | Details |